AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of December 18, 2025, AVTX stock price declined to $18.91 with 610,363 million shares trading.

AVTX has a beta of 1.48, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.09 to the broad based SPY ETF.

AVTX has a market cap of $342.91 million. This is considered a Small Cap stock.

In the last 3 years, AVTX traded as high as $1,369.81 and as low as $3.39.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, VXF, IWC, DFAS, AVSC.

AVTX has outperformed the market in the last year with a price return of +101.6% while the SPY ETF gained +13.1%. AVTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +66.9% and +11.4%, respectively, while the SPY returned +2.9% and -1.1%, respectively.

AVTX support price is $18.17 and resistance is $20.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.